Protara Therapeutics Inc (TARA)
2.89
-0.02
(-0.69%)
USD |
NASDAQ |
May 06, 16:00
2.91
+0.02
(+0.69%)
After-Hours: 20:00
Protara Therapeutics Cash from Financing (TTM): -0.103M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.103M |
December 31, 2023 | -0.091M |
September 30, 2023 | -0.091M |
June 30, 2023 | -0.082M |
March 31, 2023 | -0.082M |
December 31, 2022 | -0.09M |
September 30, 2022 | -0.09M |
Date | Value |
---|---|
June 30, 2022 | -0.072M |
March 31, 2022 | -0.072M |
December 31, 2021 | -0.228M |
September 30, 2021 | 10.49M |
June 30, 2021 | 150.32M |
March 31, 2021 | 149.94M |
December 31, 2020 | 189.40M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.228M
Minimum
Dec 2021
189.40M
Maximum
Dec 2020
35.65M
Average
-0.082M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
AngioDynamics Inc | -59.25M |
Regulus Therapeutics Inc | 11.82M |
Bio-Path Holdings Inc | -- |
Outset Medical Inc | 43.65M |
AN2 Therapeutics Inc | 84.99M |